tbuckley/cabot-search huggingface dataset:
Manuscripts Approved for JNCI, November-December 1974
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Manuscripts Approved for JNCI, November-December 1974 Get access JNCI: Journal of the National Cancer Institute, Volume 54, Issue 1, January 1975, Pages 284–286, https://doi.org/10.1093/jnci/54.1.284c Published: 01 January 1975
Septic arthritis due to group G streptococcus
Authors: N. K. Fujita
Journal: JAMA (1982)

A VARIETY of serious infections due to Lancefield group<i>G Streptococcus</i>have been reported.<sup>1-6</sup>These infections often have occurred in patients with underlying debilitating conditions. We describe a chronic alcoholic patient with group G streptococcal septic arthritis, who had a complicated course despite high-dose penicillin therapy. The case is compared with two previously reported cases of group G streptococcal arthritis. <h3>Report of a Case</h3> A 67-year-old man, who was a chronic alcoholic, fell down a flight of stairs five days before hospitalization. He sustained multiple skin abrasions and experienced pain and swelling of his left knee. He sought medical help because of persistent left-knee swelling associated with diaphoresis. He had no other underlying medical problems. His temperature was 37 °C. He had multiple skin abrasions without evidence of infection. He had poor dentition and a tender, warm, and swollen left knee. On laboratory examination, peripheral leukocyte count was 18,000/cu
VIVISECTION.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Childhood hypertension.
Authors: M Uchiyama, N Hashimoto, H Hayakawa, K Yamamoto
Journal: BMJ (1977)

For accurate diagnosis of childhood hypertension, selection of appropriate manchette size according to the child age and the circumstantial size of upper limb is essentially important. In addition, except for the emergency case of hypertension, repeated measurement of blood pressure would be desirable in several weeks interval. Recently, childhood hypertension might be closely related to the abnormality of maternal gestational period caused by the strict diet and the maternal smoking. Developmental Origins of Health and Disease(DOHaD) theory is now highlighted in the pathogenesis of adulthood hypertension. To prevent hypertension of small-for-date baby in later phase of life, maternal education for child nursing should be conducted. In children, secondary hypertension caused by renal, endocrinologic, or malignant disease is predominant rather than idiopathic hypertension.
Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Authors: C.-H. Hsu, M.S. Lee, K.-H. Lee, K. Numata, S. Stein, W. Verret, S. Hack, J. Spahn, B. Liu, C. Huang, R. He, B.-Y. Ryoo
Journal: Annals of Oncology (2019)
Negative regulation of cationic nanoparticle-induced inflammatory toxicity through the increased production of prostaglandin E2 via mitochondrial DNA-activated Ly6C<sup>+</sup> monocytes: Erratum
Authors: Li Liu, Yantong Liu, Bocheng Xu, Chuyu Liu, Yanpeng Jia, Ting Liu, Chunju Fang, Wei Wang, Jun Ren, Zhiyao He, Ke Men, Xiao Liang, Min Luo, Bin Shao, Ye Mao, Henyi Xiao, Zhiyong Qian, Jia Geng, Birong Dong, Peng Mi, Yu Jiang, Yuquan Wei, Xiawei Wei
Journal: Theranostics (2019)

[This corrects the article DOI: 10.7150/thno.21693.].
Access to Essential Drugs in Poor Countries
Authors: Elton Kessel
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RHINOLITH.
Authors: W. H. Cheatham
Journal: JAMA (1885)

Louisville, Ky. My attention was called to the above subject by an article in a late medical journal. It recalled to my mind a case I had three years ago, in the person of a young gentleman 21 years of age, who had been suffering from nasal catarrh since quite young. Had been under the treatment, in the meantime, of many physicians for this affection. The young man was scrofulous in appearance. On making a careful examination of his nose, discovered well up in one nares a foreign body. It was easily reached by a pair of forceps and removed without difficulty, with some pain, followed by slight bleeding. The foreign body was about half an inch in diameter and flat; rather dish-shaped, or the shape of a large pearl button. The surface was rough like a mulberry. On sawing through the body it proved to be a rhinolith with
Reversing Ontogeny
Authors: H. Franklin Bunn
Journal: New England Journal of Medicine (1993)

Humans, other primates, and ruminants benefit from having a structurally and functionally distinct hemoglobin during fetal development. In human fetal hemoglobin (α2(γ)2), the (γ) subunit differs from the β subunit of adult hemoglobin A (α2β2) in 39 of its 146 amino acids. Consequently, fetal red cells have a relatively high affinity for oxygen, thereby facilitating the transport of oxygen across the placenta. Shortly before birth, the β-globin gene is turned on with torrential force, whereas (γ)-globin-gene expression is reduced to a mere trickle. As a result, in normal persons over six months . . .
Psychosomatic Medicine
Authors: J. Robert Swenson
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrigendum
Authors: S. Vaisrub
Journal: JAMA (1979)

For many years the American Medical Association maintained a file of adverse drug reactions voluntarily reported by physicians. The Association discontinued this activity because most physicians were reluctant to report suspect reactions or would file a report with insufficient supporting data. The AMA finally closed out its file on adverse drug reactions and transferred responsibility for future monitoring to the Food and Drug Administration. This is unfortunate, for evaluation of medical risks and hazards would be better left in the private sector than being placed with a government regulatory agency. Many factors discourage physicians from reporting adverse drug reactions, but one of the most important is uncertainty about whether an observed reaction is actually caused by a drug. This uncertainty generally results in underreporting; however, some studies conducted through retrospective chart reviews have given a false impression of the magnitude of the problem by including reactions unrelated to administered drugs.
Abstract 123A: The critical role of interleukin-8 chemokine axis in the development of benign prostatic hyperplasia (BPH)
Authors: Diandra K. Smith, Natasha Venugopal, Martha K. Terris, Bal L. Lokeshwar
Journal: Cancer Research (2019)

Abstract Benign prostatic hyperplasia (BPH), a non-malignant proliferative disease of the prostate, has a global incidence of over 210 million men aged 50 years or older. BPH is essentially a non-cancerous (non-malignant tumor) with significant morbidity. The severity varies from mild urinary retention to severe lower urinary tract symptoms (LUTS) accounting for greater than 50% of hospital visits for difficulty with urination, retention, and pain, and close to 40% of the prostate surgeries. BPH strongly associates with prostate volume that begins to increase in men aged 40 or higher. We investigated the role of chemokine and chemokine receptors in three immortalized cell lines and primary cultures derived from fresh BPH tissue following transurethral resection of the prostate. We analyzed the levels of chemokines and chemokine receptors secreted in the culture medium and in the mRNA from cells by qPCR, western blotting and Cytokine arrays. The epithelial identity of primary cultures was established by analyzing cytokeratin expression. Two natural products isolated from Allspice were identified that inhibit the growth of BPH cultures. A cell line identified as the BPH progenitor, a BPH intermediary cell line and a cell line with frank BPH features secreted a large excess of chemokine, predominantly CXCL-VIII or Interleukin-8 (IL-8). Unusually high amount of IL-8 was secreted by BPH progenitor cells and intermediate cells as compared to a stable normal prostate cell line (RWPE1) derived from the peripheral zone of the prostate, which did not secrete any IL-8 or express its receptor. The investigation found that expression of CXC receptors CXCR1, CXCR2 and an IL-8 inducible CXCR (CXCR7) was absent in progenitor cells and in intermediate cells, but was highly expressed in the cell line derived from BPH tissue and more significantly, in primary cultures of BPH tissue. Further, primary cultures and progenitor cells expressed high levels of immune stimulatory factors indicating PMN and monocyte infiltration leading to potential chronic inflammation of the transitional zone of the prostate. The natural products from Allspice inhibited all members of the IL-8 axis and proliferation, suggesting their potential preventative potential for BPH. These results demonstrate how a novel chemokine axis is likely to enhance pathogenesis of BPH and suggest several avenues to control the abnormal growth of prostate in aging male. Note: This abstract was not presented at the meeting. Citation Format: Diandra K. Smith, Natasha Venugopal, Martha K. Terris, Bal L. Lokeshwar. The critical role of interleukin-8 chemokine axis in the development of benign prostatic hyperplasia (BPH) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 123A.
Commentaire de travail de Y. Mori et al., pp.98
Journal: Endoscopy (2013)

See also: Comprehensive diagnostic ability of endocytoscopy compared with biopsy for colorectal neoplasms: a prospective randomized noninferiority trialEndoscopy 2013; 45(02): 98-105DOI: 10.1055/s-0032-1325932
Abstract 275: The Role of Fibroblast-specific Canonical TGFβ Signaling in Cardiac Fibrosis
Authors: Hadi Khalil
Journal: Circulation Research (2016)

Heart failure is a progressive disease characterized by cardiomyocyte loss, interstitial fibrosis, and chamber remodeling. During physiological conditions cardiac fibroblasts contribute to the homeostatic maintenance of myocardial structure as well as the maintenance of biochemical and electrical properties of the heart. Injury and/or cytokine stimulation activate fibroblasts which transdifferentiate into myofibroblasts. These newly formed cells secrete extracellular matrix (ECM) for wound healing and tissue remodeling through their contractile activity. Fibrosis mediated by these cells can initially be a beneficial response that acutely scarifies areas after an infarct to prevent wall rupture. However, during chronic disease states such as heart failure, persistent recruitment and activation of fibroblasts leads to excessive deposition of ECM that results in stiffening and pathological remodeling of the ventricles. During chronic heart disease, cardiomyocytes, immune cells and fibroblasts secrete the cytokine transforming growth factor-TGFβ, which activates fibroblasts and promotes their conversion to myofibroblasts. Previous work from Kass lab showed that manipulation of TGFβ by deletion of Tgfbr 1 (type I TGFβ receptor) in cardiomyocytes reduced the fibrotic response after pressure overload. However heart failure was not improved because deleterious TGFβ signaling in fibroblasts persisted. Here we utilized a novel myofibroblast-specific inducible Cre-expressing mouse line (Periostin-MerCreMer) to examine canonical (Smad2/3) TGFβ signaling to determine how these cells and their activation mediate disease in heart failure. Our data indicate that myofibroblast-specific deletion of Smad3 but not Smad2 was sufficient to significantly inhibit myocardial fibrosis after pressure overload, but not ultimately prevent it. Also, myofibroblast specific Smad2/3 double nulls and Tgfbr1/2 double nulls were generated and analyzed. Data from all these myofibroblast-specific mouse models with inhibited TGFβ signaling indicated that TGFβ initiates myofibroblast transformation and myocardial fibrosis with injury to the heart, but that ultimately other pathways can fully compensate and fibrosis eventually occurs.
A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.
Authors: Albert Font Pous, Miguel Angel Climent Duran, Ignacio Duran, Begona Mellado, Jesus Paramio, Francisco X. Real, Jose Luis Ramirez, Juan Luis Sanz, Daniel E. Castellano
Journal: Journal of Clinical Oncology (2019)

TPS501 Background: Niraparib (N) is an orally selective poly(ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of patients (pt) with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after complete or partial response to platinum-based chemotherapy (CT). Cabozantinib (C) is a tyrosine kinase (TK) inhibitor with activity against TKs including VEGFR2, MET and AXL, approved on kidney cancer pt after TK failure, that has demonstrated clinical activity in heavily pretreated, advanced UC pt. c-Met receptor TK is activated in urothelial carcinoma (UC) cells. c-Met activity can decrease response to PARP inhibitors, whereas treatment with c-Met inhibitors renders cells more sensitive to PARP inhibition. UC pt with tumors overexpressing c-Met may benefit from the combination of c-Met and PARP inhibitors. This multicenter, open-label phase (ph) I-II study is to explore the maximum-tolerated dose (MTD) of N + C combination in pt with advanced genitourinary malignancies (UC and kidney cancer) follow by a preliminary efficacy of the combination in advanced UC. Methods: Eligible pt have confirmed histopathology of UC or clear cell renal cell carcinoma, advanced or metastatic disease, age ≥18 years, ECOG PS ≤1, progressive disease after platinum-based CT, measurable lesions, no prior therapy with PARP or c-Met inhibitors and adequate bone marrow, liver and renal functions. The ph I portion is enrolling ≈24 pt to identify the MTD proposed to use in a ph II (RP2D). Pt will receive N and C p.o. once daily in 28-day cycles: Dose level 1 (DL1) N/C 100/20 mg; DL2 200/20 mg; DL3 200/40 mg; DL4 200/60 mg. Pt will be accrued to each dose level in cohorts of 6 pt until the MTD is achieved (the highest dose at which ≤1 out of 6 pt experience a dose-limiting toxicity [DLT]). DLT will be evaluated during the first 2 cycles. The ph 2 portion will enroll 51 UC pt to receive the RP2D. Tumor response will be assessed per RECIST v1.1. Endpoints of the ph 2 are 6-month PFS (primary), overall response rate, disease control rate, duration of response, PFS and OS. Tissue and plasma sample will be collected for translational study. Clinical trial information: NCT03425201.
Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer.
Authors: Eric Roeland, Kelly Anne Shimabukuro, Paul Timothy Fanta, Bethany H. Parker, Michael Hwang, Tony R. Reid
Journal: Journal of Clinical Oncology (2012)

473 Background: In mCRC, bevacizumab studies have shown improved survival in 5-FU based chemotherapy. Therapeutic inhibition of angiogenesis pathways may improve response of chemotherapy refractory malignancies. We evaluated the combination of axitinib, a VEGF receptor inhibitor, used intermittently with 5-FU based chemotherapy for refractory mCRC. We hypothesized that intermittent pulse dosed axitinib may improve response by delivering chemotherapy during tumor reperfusion after release from angiogenesis inhibition. We present preliminary data of the Phase I portion evaluating the safety and efficacy of interrupted pulse dosed axitinib + FOLFIRI. Methods: Initially, Pfizer A4061020 was a phase IB study of axitinib + bevacizumab + FOLFOX vs. FOLFIRI to evaluate potential overlapping toxicities. In cohorts 8 and 9, A4061020 was expanded to determine the MTD of 7 days of intermittent pulse dosed axitinib at 14mg vs. 20mg + FOLFIRI or FOLFOX. Enrollment was open to mCRC with progression on both oxaliplatin and irinotecan-based regimens. The primary outcome was MTD; while secondary outcomes included: PFS, TTP, and OS. Results: Preliminary data of 10 mCRC subjects show intermittent pulse dosed axitinib at 14mg and 20mg in combination treatment is safe and tolerable (few grade 3 and one grade 4 AE). We observed PFS up to 16.8 mos (avg 8.7 mos, 6 subjects) and TTP up to 17.1 mos (avg 11.8 mos, 4 subjects) vs. average 6 mos on the last line of chemotherapy. To date, the OS endpoint has not been achieved ( Table ). Conclusions: In 10 heavily pre-treated mCRC subjects, intermittent pulse dosed axitinib demonstrates safety, tolerability, and improved PFS and TTP. Intermittent pulse-dosed VEGF receptor inhibition may enhance tumor response that warrants further exploration. [Table: see text]
Sclerotherapy continues to undergo evaluation
Authors: K. Simmons
Journal: JAMA (1984)

Findings from the first prospective, controlled study of chronic esophageal sclerotherapy from the United States have become available. Jacob Korula, MD, assistant professor of medicine at the University of Southern California (USC) School of Medicine, Los Angeles, reported at the recent meeting of the American Association for the Study of Liver Diseases in Chicago that sclerotherapy "appears to decrease bleeding risk and transfusion requirements, and to prolong the bleeding-free interval," but it doesn't appear to increase survival. According to Korula, only one other prospective, fully controlled study of intravariceal sclerotherapy has emerged from the field. That one was done in England (<i>Lancet</i>1982;1:124-127). In this country, the treatment has been studied intensely only for the last four to five years. At the time of the meeting, Korula and co-workers at USC's liver unit, Rancho Los Amigos Hospital, Downey, Calif, had treated 120 patients who had portal hypertension: 63 were randomized
ASSOCIATION NEWS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice
Authors: D Zavaglia
Journal: Molecular Therapy (2003)

VP22, a protein of the herpes simplex virus tegument, can form complexes with fluorescein-labeled oligonucleotides. These particles, termed “Vectosomes,” are efficiently taken up by cells and remain stable in the cell cytoplasm without any particular activity. Interestingly, these Vectosomes can be disrupted by light, which releases the antisense activity. Here we show that anti-c-raf1 Vectosomes are efficiently activated by light in vivo after injection into subcutaneous A549 (non-small-cell lung cancer) tumors implanted in nude mice. Moreover, two injections per week of anti-c-raf1 Vectosomes followed by illumination result in a stronger inhibition of tumor growth than injections of the antisense alone or of the different control Vectosomes. This effect correlates with a strong inhibition of the c-Raf1 protein expression. As a consequence of c-Raf1 loss, apoptosis was also detected in these tumors. Vectosomes thus represent a new powerful tool to improve the delivery of oligonucleotides in vitro and in vivo.